JP2018515442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515442A5 JP2018515442A5 JP2017552910A JP2017552910A JP2018515442A5 JP 2018515442 A5 JP2018515442 A5 JP 2018515442A5 JP 2017552910 A JP2017552910 A JP 2017552910A JP 2017552910 A JP2017552910 A JP 2017552910A JP 2018515442 A5 JP2018515442 A5 JP 2018515442A5
- Authority
- JP
- Japan
- Prior art keywords
- flt
- composition
- antibody
- binding fragment
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 38
- 102000036639 antigens Human genes 0.000 claims description 38
- 108091007433 antigens Proteins 0.000 claims description 38
- 239000012634 fragment Substances 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 34
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims description 22
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims description 22
- 238000003556 assay Methods 0.000 claims description 10
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 10
- 210000004072 lung Anatomy 0.000 claims description 8
- 238000000159 protein binding assay Methods 0.000 claims description 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 6
- 241000282693 Cercopithecidae Species 0.000 claims description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 2
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 2
- 101150062285 PGF gene Proteins 0.000 claims description 2
- 102100035194 Placenta growth factor Human genes 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 239000000168 bronchodilator agent Substances 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 210000003754 fetus Anatomy 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 230000004199 lung function Effects 0.000 claims description 2
- 230000032646 lung growth Effects 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 238000002640 oxygen therapy Methods 0.000 claims description 2
- 201000004193 respiratory failure Diseases 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 40
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000008467 tissue growth Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144241P | 2015-04-07 | 2015-04-07 | |
| US62/144,241 | 2015-04-07 | ||
| PCT/US2016/026420 WO2016164567A1 (en) | 2015-04-07 | 2016-04-07 | Anti-flt-1 antibodies in treating bronchopulmonary dysplasia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515442A JP2018515442A (ja) | 2018-06-14 |
| JP2018515442A5 true JP2018515442A5 (enExample) | 2019-05-16 |
| JP6797826B2 JP6797826B2 (ja) | 2020-12-09 |
Family
ID=55969453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552910A Active JP6797826B2 (ja) | 2015-04-07 | 2016-04-07 | 気管支肺異形成症の治療における抗Ｆｌｔ−１抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10738123B2 (enExample) |
| EP (1) | EP3280737B1 (enExample) |
| JP (1) | JP6797826B2 (enExample) |
| CN (1) | CN107690335A (enExample) |
| AU (1) | AU2016246730B2 (enExample) |
| BR (1) | BR112017021413A2 (enExample) |
| CA (1) | CA2982815A1 (enExample) |
| HK (1) | HK1249908A1 (enExample) |
| MA (1) | MA41908A (enExample) |
| MX (2) | MX391847B (enExample) |
| WO (1) | WO2016164567A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX385370B (es) * | 2016-03-31 | 2025-03-18 | Immutrix Therapeutics Inc | Metodo para el tratamiento extracorporeo de preeclampsia y trastornos relacionados. |
| WO2019246521A1 (en) | 2018-06-22 | 2019-12-26 | Shire Human Genetic Therapies, Inc. | Anti-flt-1 antibodies in treating bronchopulmonary dysplasia |
| EP3936054A1 (en) * | 2020-07-08 | 2022-01-12 | Assistance Publique - Hôpitaux de Paris | Method of prognosis of bronchopulmonary dysplasia in premature infants |
| MX2024002112A (es) * | 2021-08-16 | 2024-05-03 | Janssen Biotech Inc | Anticuerpos anti-vegfr1 y sus usos. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7335362B2 (en) * | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
| US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| KR101215701B1 (ko) * | 2002-07-19 | 2012-12-26 | 베스 이스라엘 데코니스 메디칼 센터 | 자간전증 또는 자간의 진단 및 치료 방법 |
| CN102397542B (zh) | 2004-11-18 | 2014-05-07 | 英克隆有限责任公司 | 抗血管内皮生长因子受体-1的抗体 |
| US20060153835A1 (en) * | 2005-01-12 | 2006-07-13 | Smith Henry J | Treatment of pre-eclampsia in pregnant women using targeted apheresis |
| US8349325B2 (en) * | 2008-12-23 | 2013-01-08 | Abbott Laboratories | Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making |
| WO2012109282A2 (en) * | 2011-02-07 | 2012-08-16 | Agamin Pharmaceuticals, Llc | Methods and systems for treating or preventing pregnancy-related hypertensive disorders |
| CA2898998C (en) * | 2013-01-28 | 2023-02-14 | Regents Of The University Of Minnesota | Anti-flt-1 antibodies in treating duchenne muscular dystrophy |
| TW201517916A (zh) | 2013-03-15 | 2015-05-16 | Lilly Co Eli | Ｖｅｇｆｒ１抗體之治療用途 |
-
2016
- 2016-04-07 HK HK18109294.4A patent/HK1249908A1/zh unknown
- 2016-04-07 AU AU2016246730A patent/AU2016246730B2/en active Active
- 2016-04-07 MX MX2017012827A patent/MX391847B/es unknown
- 2016-04-07 JP JP2017552910A patent/JP6797826B2/ja active Active
- 2016-04-07 CN CN201680032805.1A patent/CN107690335A/zh active Pending
- 2016-04-07 US US15/564,969 patent/US10738123B2/en active Active
- 2016-04-07 MA MA041908A patent/MA41908A/fr unknown
- 2016-04-07 WO PCT/US2016/026420 patent/WO2016164567A1/en not_active Ceased
- 2016-04-07 BR BR112017021413A patent/BR112017021413A2/pt not_active Application Discontinuation
- 2016-04-07 EP EP16722725.5A patent/EP3280737B1/en active Active
- 2016-04-07 CA CA2982815A patent/CA2982815A1/en active Pending
-
2017
- 2017-10-05 MX MX2022004164A patent/MX2022004164A/es unknown
-
2019
- 2019-12-05 US US16/704,861 patent/US20200362041A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516647A5 (enExample) | ||
| JP2018515442A5 (enExample) | ||
| JP2024150751A5 (enExample) | ||
| CN105073133B (zh) | 抗gdf15抗体 | |
| JPWO2018191479A5 (enExample) | ||
| WO2020252349A1 (en) | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer | |
| JP2009541374A5 (enExample) | ||
| Menzella et al. | Tailored therapy for severe asthma | |
| JP2020512281A5 (enExample) | ||
| JP2010520290A5 (enExample) | ||
| JP2017507652A5 (enExample) | ||
| JP2017507139A5 (enExample) | ||
| JP2011506483A5 (enExample) | ||
| JP2017535547A5 (enExample) | ||
| JP2009533367A5 (enExample) | ||
| JP2019505527A5 (enExample) | ||
| JP2019513726A5 (enExample) | ||
| JP2016094424A5 (enExample) | ||
| JP2013516454A5 (enExample) | ||
| EP3347054A1 (en) | Dosing regimens for anti-tf-antibody drug-conjugates | |
| JP2021509668A (ja) | 免疫抑制なしにｉｌ−６媒介性炎症を処置する方法 | |
| JP2013508292A5 (enExample) | ||
| JP2017507945A5 (enExample) | ||
| JP2020504135A5 (enExample) | ||
| JP2019526244A5 (enExample) |